Goat IgG ELISA Kit

Name: Goat IgG ELISA Kit
SKU: DEIA640
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum and Plasma

Species Reactivity

Goat

Detection Method

Sandwich-ELISA

Intended Use

This ELISA kit is designed for measurement of IgG in goat serum and plasma.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Anti Goat IgG Coated 96-well Plate	12×8 wells	-20°C
2	HRP Conjugate Stock	50 ul	-20°C
3	Goat IgG Stock (lyophilized)	3 vials	-20°C
4	20× Wash Solution	50 ml	2-8°C
5	10× Diluent	25 ml	2-8°C
6	TMB Reagent	11 ml	2-8°C
7	Stop Solution	11 ml	2-8°C

Storage

The kit will remain stable for six months from the date of purchase provided that the components are stored appropriately. Store the 96-well plate, HRP conjugate stock and IgG stock vials at or below - 20°C. Store the remaining components in the refrigerator at 2-8°C. The microtiter plate should always be kept in a sealed bag with desiccant to minimize exposure to damp air.

Standard Curve

A typical standard curve with optical density readings at 450 nm on the Y-axis against IgG concentrations on the X-axis is shown below. This curve is for the purpose of illustration only and should not be used to calculate unknowns. A standard curve should be generated in each experiment.
DEIA640-Typical Standard Curve

Citations

Have you cited DEIA640 in a publication? Let us know and earn a reward for your research.

Persistence of maternal antibodies against goat pox virus in goat kids

Abdollahi M, Lotfi M, Lotfollahzadeh S, Dezfouli MRM, Adibi M, Kamalzadeh M, Firuzyar S

J Vet Intern Med2024 OctPubMed ID: 39086156Read Article

Applications: ELISA
Reactive species: Goat
"Abstract: Background:In goat kids, choosing the appropriate age to administer the first dose of goat pox disease (GTP) vaccine requires knowing when maternal antibody decline concentrations. Objective:Determine the persistence of maternal antibodies against goat pox virus (GTPV) in goat kids. Animals:Twenty Saanen goat kids from birth to 120 days old. Methods:In 2 groups, including: control (receiving colostrum from nonvaccinated does) and treatment (receiving colostrum from vaccinated does). On zero, 3, 7, 14, 21, 28, 42, 56, 70, 100 and 120 days after the birth, virus neutralization test was used to measure the serum concentration of antibodies against GTPV. Results:At the age of 56 days, the first seronegative goat kids (n = 2) were recorded in the treatment group. At the age of 120 days, all the goat kids in the treatment group were seronegative. The average virus neutralization index (VNI) of the goat kids became negative at the age of 100 to 120 days. All goat kids in the control group were negative at all times. Conclusions and clinical importance:One hundred to 120 days of the age seems to be the time to administer the first GTP vaccine in the goat kids with passive immunity against goat pox."
Article snippet: Measurement of IgG serum concentration by ELISA method (DEIA640, CD Creative Diagnostics, Shirley, USA) at 48 hours after birth showed that all the studied kids had no failure of passive transfer (FPT) [cut‐off: 10 mg/mL].

Documents

pdf COA

pdf SDS

pdf Datasheet

Immunoassays for Process-related Impurities

QA & Reviews

Customer Reviews

References

Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris

FRONTIERS IN IMMUNOLOGY

Authors: Meier, Katharina; Holstein, Julia; Solimani, Farzan; Waschke, Jens; Ghoreschi, Kamran

Abstract

Background In pemphigus, elucidating the disease-causing immune mechanism and developing new therapeutic strategies are needed. In this context, the second messenger 3 ',5 '-cyclic adenosine monophosphate (cAMP) is gaining attention. cAMP is important in hematological and auto-inflammatory disorders. A class of enzymes called phosphodiesterases (PDEs) control intracellular cAMP levels. In pemphigus, cAMP levels increase following IgG binding to Dsg3. This appears to be a mechanism to preserve epithelial integrity. Objectives To determine whether apremilast, an inhibitor of the PDE4 normally used in psoriasis, may be of benefit in the blistering skin disorder pemphigus. Methods Here we report of a 62 years old patient with chronic debilitating and recalcitrant pemphigus not responding to several previous treatments, who received treatment with apremilast over a period of 32 weeks. Desmoglein autoantibody levels were assessed by Enzyme-linked Immunosorbent Assay (ELISA), whereas disease severity and quality of life were assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In an attempt to explain the effects of apremilast in pemphigus, peripheral blood mononuclear cells (PBMCs) were analyzed for the duration of treatment by flow cytometry for the distribution of specialized T cell subsets. The frequencies of circulating T helper (Th) 1, Th2, Th17, Th17.1 and T follicular helper (Tfh) 1, Tfh2, Tfh17, and Tfh17.1 were analyzed by CCR6, CXCR3, and CXCR5 expression of CD4(+) T cells. Further, based on the different expressions of CXCR5, CD127, and CD25, we analyzed the T regulatory (Treg) and T follicular regulatory (Tfreg) compartment. Results In response to apremilast treatment, Dsg-specific autoantibody titers decreased, blistering ceased and lesions healed, showing a long-lasting effect. While the frequencies of most of the Th and Tfh cell subsets remained unchanged, we observed a continuous increase in Treg and Tfreg cell levels. Conclusion Our findings are encouraging and warrant extension of the beneficial effect of PDE4 inhibition on a larger cohort of pemphigus patients.

Seroprevalence of Jamestown Canyon virus in the Japanese general population

BMC INFECTIOUS DISEASES

Authors: Kato, Hirofumi; Satoh, Masaaki; Kawahara, Madoka; Kitaura, Satoshi; Yoshikawa, Tomoki; Fukushi, Shuetsu; Dimitrova, Kristina; Wood, Heidi; Saijo, Masayuki; Takayama-Ito, Mutsuyo

Abstract

Background Jamestown Canyon virus (JCV) is a mosquito-borne orthobunyavirus that causes acute febrile illness, meningitis, and meningoencephalitis, mainly among adults. JCV is widely distributed in North America and the number of JCV cases in the U.S. has increased in recent years. Therefore, the central nervous system disease caused by JCV can be considered a potentially re-emerging viral disease. However, the seroprevalence of JCV is unknown in Japan. The purpose of this study is to evaluate the seroprevalence of JCV in the Japanese population. Methods We used an IgG enzyme-linked immunosorbent assay (IgG-ELISA) with JCV-infected cell-lysates and/or a neutralizing (NT) antibody assay. The cut-off value of IgG-ELISA was determined using IgG-ELISA to analyze serum specimens from 37 healthy Japanese donors. IgG-ELISA was validated by assessing its sensitivity and specificity, using 38 human serum samples previously tested for the presence or absence of antibodies against JCV and snowshoe hare virus (SSHV), in an in-house NT antibody assay conducted by the Public Health Agency of Canada. The seroepidemiological study was performed using IgG-ELISA and NT antibody assay to analyze 246 human serum samples from the serum bank of the National Institute of Infectious Diseases (NIID) in Japan. Results The cut-off value of IgG-ELISA was determined at 0.20, based on the mean (- 0.075) and standard deviation (0.092) values using Japanese donors' sera. The sensitivity and the specificity of IgG-ELISA determined using 25 JCV-positive and 4 JCV-negative serum samples were 96 and 100%, respectively. Analysis of the 246 Japanese serum samples revealed that no specimen showed a higher value than the cut-off value of IgG-ELISA, and no sample tested positive by the NT antibody assay. Conclusions Our results showed that JCV is not circulating significantly in Japan. To the best of our knowledge, this is the first report to demonstrate the seroprevalence of JCV in the general population in Japan.